Cargando…
Secukinumab, Pituitary Enlargement and Panhypopituitarism: Are They Related?
Pituitary adenomas are the most common cause of hypopituitarism associated with pituitary enlargement, but other aetiologies have been emerging, namely immune checkpoint inhibitor-induced hypophysitis (ipilimumab, nivolumab and pembrolizumab). Secukinumab is a recently approved human monoclonal anti...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SMC Media Srl
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765694/ https://www.ncbi.nlm.nih.gov/pubmed/35059351 http://dx.doi.org/10.12890/2021_003099 |